RxDoctor Payments Data

Max Shenin, DO

Rheumatology · Wilmington, NCNPI 1730380239

Payments from drug & device makers

$1,575in general payments, 2019–2025

Across 13 payments — averaging $121.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$36
  • GSK$34
  • Amgen$28
  • Sobi, Inc$17
  • Actelion Pharmaceuticals US, Inc.$16
  • plus $27 from 2 others

What the payments were for

  • Speaking & faculty fees$1,37587%
  • Food & beverage$20013%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,575 in reported general payments places this provider in the 35th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$131,387
Medicare patients
502
Services billed
4,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orencia ClickjectAbatacept84$460,056
OrenciaAbatacept/Maltose97$440,901
ForteoTeriparatide105$420,152
Humira(Cf) PenAdalimumab54$365,599
OtezlaApremilast54$267,754
Humira PenAdalimumab20$261,241
Simponi AriaGolimumab28$198,965
ProliaDenosumab113$182,466
OrenciaAbatacept33$173,415
Cimzia (2 Pack)Certolizumab Pegol26$139,049
Enbrel SureclickEtanercept22$138,462
SimponiGolimumab16$93,613
XeljanzTofacitinib Citrate19$78,053
Xeljanz XrTofacitinib Citrate12$69,601
Infliximab12$24,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$28$450,220167 claims
Johnson & JohnsonSimponi Aria, Simponi$12$292,57744 claims
UCB, Inc.Cimzia (2 Pack)$36$139,04926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →